Dietmar Hopp's family began providing angel funding to European biotechs in 2001 before pairing up with advisory firm dievini GmbH in 2005 to form dievini Hopp BioTech Holding GmbH & Co. KG. Since then, the firm has invested more than €800M ($1 billion) in companies with a focus on innovative products for cancer, neurodegenerative disorders and personalized medicine, as well as molecular diagnostics and drug delivery technologies. (A) Year of first investment; Source: dievini Hopp



Disease focus

First investment

2006 stake

2012 stake